Abstract:
An energy exchanger is provided. The exchanger includes a housing having a front and a back. A plurality of panels forming desiccant channels extend from the front to the back of the housing. Air channels are formed between adjacent panels. The air channels are configured to direct an air stream in a direction from the front of the housing to the back of the housing. A desiccant inlet is provided in flow communication with the desiccant channels. A desiccant outlet is provided in flow communication with the desiccant channels. The desiccant channels are configured to channel desiccant from the desiccant inlet to the desiccant outlet in at least one of a counter-flow or cross-flow direction with respect to the direction of the air stream.
Abstract:
Compositions and methods are provided for modulating an immune response in a vertebrate subject. Compositions and methods can comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to activate the immune response in the vertebrate subject, wherein the modified host defense peptide is inverted in amino acid sequence from an amino terminus to a carboxy terminus or modified to one or more D-amino acids, or both modifications, when compared to a host defense peptide. Compositions and methods are provided which comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to modify an immune response in the vertebrate subject.
Abstract:
Systems and methods of controlling user interaction with an application. The systems and methods include executing an application, providing a graphical overlay coupled to the application where the graphical overlay is configured to display a visualization or a visual effect, measuring at least one engagement characteristic to provide a measured condition and providing the visualization based on the measured condition. Examples of engagement characteristic include user physiological condition, type of the application selected, duration of time spent interacting with the application, duration of time spent interacting with one or more input receiving devices, pressure exerted over one or more input receiving devices and noise level of the user.
Abstract:
Compositions and methods for stimulating an immune response against a secreted enterohemorragic Escherichia coli (EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.
Abstract:
Cloning and expression of genes encoding H. somnus transferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. somnus infections.
Abstract:
Immunogenic proteins comprising Mycoplasma mycoides subsp. mycoides and M. mycoides subsp. capri proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to prevent M. mycoides subsp. mycoides infections are disclosed.
Abstract:
The disclosure provides radiolabeled and/or cytotoxin labelled antibodies and methods and uses of these antibodies. In one embodiment, provided is a cytotoxic agent comprising an antibody that specifically binds a target disease cell surface receptor, a cytotoxin, and a radiolabel, wherein the cytotoxin is linked directly or indirectly to the antibody, and wherein the radiolabel comprises a radionuclide and optionally a scaffold, wherein the scaffold is directly or indirectly coupled to the antibody. Also provided are methods of preparing the cytotoxic agent and methods of treating disease using the cytotoxic agent.
Abstract:
The disclosure relates to antibodies that bind human, murine, and canine IGF2R, and methods of using said antibodies. Provided herein are antibodies having specific CDRs identified herein, including functional variants of specific variable domains and IgGs having the specified CDR sequences, and immunoconjugates of said antibodies and uses thereof. Also provided herein are compositions and kits comprising said antibodies, and methods and uses of said antibodies, immunoconjugates, compositions, and kits. Also provided herein are the use of said antibodies for radioimmunotherapy (RIT) for cancer including osteosarcoma.
Abstract:
L intracellularis antigens for use in subunit vaccine compositions to elicit immune responses against L intracellularis infections such as proliferative enteropathy (PE) are described, as well as polynucleotides encoding therefor. Also described are methods for treating and preventing L intracellularis infections.